Plasma pharmacokinetics and tissue penetration of alatrofloxacin in morbidly obese individuals

Clinical Drug Investigation

Volumn 21, Issue 3, 2001, Pages 219-224

  Pai, Manjunath P ^a,b   Bordley IV, James ^b   Amsden, Guy W ^a,b  

^a BASSETT RESEARCH INSTITUTE   (United States)

^b BASSETT HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALATROFLOXACIN; TROVAFLOXACIN;

ADIPOSE TISSUE; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PENETRATION; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MORBID OBESITY; PERITONEUM; PRIORITY JOURNAL; ROUX Y ANASTOMOSIS;

EID: 0035091583     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200121030-00008     Document Type: Article

References (5)

1. Teng R, Vincent J, Baris B, et al. Pharmacokinetics of single and multiple doses of alatrofloxacin, the prodrug of CP-99,219, in healthy male volunteers [abstract F240]. In: Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA. Washington, DC: American Society for Microbiology: 1995; 155
2. Brightly KE, Gootz TD. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother 1997; 39 Suppl. B: 1-14
3. Nagachinta T, Stephens M, Reitz B, et al. Risk factors for surgical wound infection following cardiac surgery. J Infect Dis 1987; 156: 967-73
4. Nystrom PO, Jonstam A, Hojer H, et al. Incisional infection after colorectal surgery in obese patients. Acta Chir Scand 1987; 153: 225-7
5. Vincent J, Venitz J, Teng R, et al. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of prodrug, alatrofloxacin. J Antimicrob Chemother 1997; 39 Suppl. B: 75-80